Posts

Posted on

Hudbay Announces Closing of $600 Million Strategic Investment from Mitsubishi Corporation for 30% Joint Venture Interest in Copper World

TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) is pleased to announce the closing of the previously announced strategic investment from Mitsubishi Corporation (“Mitsubishi”) for a 30% joint venture interest (the “JV Transaction”) in Copper World LLC, which owns the fully-permitted Copper World project in Arizona (“Copper World”). On closing, Mitsubishi contributed approximately $420 million of cash to Copper World LLC, and it will contribute an additional $180 million in cash to complete its initial investment within 18 months in accordance with the terms of the definitive subscription agreement, as further described in Hudbay’s August 13, 2025 news release. Mitsubishi will also fund its pro-rata 30% share of future equity capital contributions required to construct Copper World. All dollar amounts are in U.S. dollars, unless otherwise noted.

“Closing of the JV Transaction with Mitsubishi marks the beginning of a long-term strategic partnership, an exciting new chapter for Copper World and an important growth milestone for Hudbay,” said Peter Kukielski, Hudbay’s President and Chief Executive Officer. “Thanks to the collaborative efforts between the Hudbay and Mitsubishi teams, we are pleased to welcome our new Copper World joint venture partner. This strategic partnership will leverage our organizations’ complementary strengths to deliver this world-class project that will increase Hudbay’s consolidated copper production by more than 50% and create significant value for all of our stakeholders. We are ideally positioned to build one of the next major copper mines in the U.S. and produce ‘Made in America’ copper for the U.S. critical minerals supply chain.”

Hudbay Continues to Prudently Advance Copper World Towards a Sanction Decision in 2026

  • Realized Accretive JV Transaction – The successful closing of the highly accretive $600 million JV Transaction represents a significant de-risking milestone in advancing Copper World and further validates the premium long-term value of this world-class asset. The $420 million of proceeds from Mitsubishi will be used to directly fund the remaining definitive feasibility study (“DFS”) costs and pre-sanction costs in addition to the initial project development costs for Copper World. Mitsubishi will contribute an additional $180 million within 18 months to complete its initial investment and will also fund its pro-rata 30% share of future equity capital contributions. The JV Transaction increases the project IRR to Hudbay to approximately 90% based on pre-feasibility study (“PFS”) estimatesi.
  • Secured Premier Strategic Joint Venture Partner – Mitsubishi is one of the largest Japanese trading houses with a global mining presence and a significant U.S.-based business. Mitsubishi is the partner of choice with investments in a world-class portfolio of large and high-quality copper assets, including five of the top twenty copper mines globally by 2024 production. This partnership validates the attractive long-term value of Copper World as a world-class copper asset and endorses the strong technical capabilities of Hudbay. It also represents the beginning of a long-term strategic partnership, and the parties are identifying other opportunities for collaboration to advance their respective copper growth strategies.
  • Achieved Key Elements of Hudbay’s Three Prerequisites (3-P) Plan – Hudbay has achieved the final key elements of its prudent 3-P financial strategy for the development of Copper World with the closing of the JV Transaction and the achievement of stated balance sheet targets. Before accounting for proceeds from the JV Transaction, Hudbay has already achieved more than $600 million in cash and cash equivalents and reduced its net debt to adjusted EBITDA ratio to 0.5x as of September 30, 2025, far exceeding the stated balance sheet targets. The Mitsubishi initial investment and its future pro-rata equity capital contributions, together with the Wheaton Precious Metals Corp. streamii, provide significant financial flexibility by reducing Hudbay’s estimated share of the remaining capital contributions to approximately $200 million based on PFS estimates and deferring Hudbay’s first capital contribution to 2028 at the earliest.
  • Feasibility Study and Detailed Engineering Underway – Feasibility activities for Copper World are well underway with expected completion of the DFS in mid-2026. Hudbay has continued to execute detailed engineering work and other de-risking activities, in preparation for a Copper World sanction decision expected in 2026.

Forward-Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities legislation. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.

Forward-looking information includes, but is not limited to, expectations regarding the anticipated benefits of the JV Transaction to Hudbay, Mitsubishi and the United States, the consummation and timing of the DFS, Hudbay’s expectations for the Copper World project, including its project sanctioning timelines, future spending, project economics, future production profile and life of mine plan, and the benefits, timing and consummation of the amended Wheaton Precious Metals Corp. stream agreement. Forward-looking information is not, and cannot be, a guarantee of future results or events. Forward-looking information is based on, among other things, opinions, assumptions, estimates and analyses that, while considered reasonable at the date the forward-looking information is provided, inherently are subject to significant risks, uncertainties, contingencies and other factors that may cause actual results and events to be materially different from those expressed or implied by the forward-looking-information.

The material factors or assumptions that Hudbay identified and were applied in drawing conclusions or making forecasts or projections set out in the forward-looking information include, but are not limited to, obtaining the minor permits required for Copper World Phase I, no significant unanticipated challenges, litigation or delays to the advancement of Copper World, maintaining the Company’s 3-P plan for sanctioning Copper World, including the DFS meeting the targeted IRR, no change in legislation or regulations and no other political or economic developments that would impact the Company’s ability to advance Copper World.

Should one or more risk, uncertainty, contingency or other factor materialize or should any factor or assumption prove incorrect, actual results could vary materially from those expressed or implied in the forward-looking information. Accordingly, you should not place undue reliance on forward-looking information. Hudbay does not assume any obligation to update or revise any forward-looking information after the date of this news release or to explain any material difference between subsequent actual events and any forward-looking information, except as required by applicable law.

About Hudbay

Hudbay (TSX, NYSE: HBM) is a copper-focused critical minerals mining company with three long-life operations and a world-class pipeline of copper growth projects in tier-one mining jurisdictions of Canada, Peru and the United States.

Hudbay’s operating portfolio includes the Constancia mine in Cusco (Peru), the Snow Lake operations in Manitoba (Canada) and the Copper Mountain mine in British Columbia (Canada). Copper is the primary metal produced by the Company, which is complemented by meaningful gold production and by-product zinc, silver and molybdenum. Hudbay’s growth pipeline includes the Copper World project in Arizona (United States), the Mason project in Nevada (United States), the Llaguen project in La Libertad (Peru) and several expansion and exploration opportunities near its existing operations.

The value Hudbay creates and the impact it has is embodied in its purpose statement: “We care about our people, our communities and our planet. Hudbay provides the metals the world needs. We work sustainably, transform lives and create better futures for communities.” Hudbay’s mission is to create sustainable value and strong returns by leveraging its core strengths in community relations, focused exploration, mine development and efficient operations.

For further information, please contact:

Candace Brûlé
Senior Vice President, Capital Markets & Corporate Affairs
(416) 362-8181
[email protected]

______________________________
i Based on the initial capital investment and the $3.75 per pound copper price used in the PFS published on September 8, 2023 with assumptions of approximately $145 million for pre-sanctioning costs, $230 million from the precious metals stream, $350 million from project-level financing and approximately $700 million from Mitsubishi’s $420 million initial investment, $180 million investment within 18 months and its pro-rata 30% share of future equity capital contributions.
ii For further information regarding the terms agreed to with Wheaton Precious Metals Corp. to enhance and amend the existing precious metals streaming agreement, please see Hudbay’s August 13, 2025 news release.



Posted on

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Significant Unmet Need Remains in this Setting

Over 14,000 Patients are Eligible for 2L+ Treatment in This Setting in the United States Each Year

Summit Enters 2026 with Approximately $710 Million in Cash

MIAMI–(BUSINESS WIRE)–
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for ivonescimab, the novel, first-in-class investigational bispecific antibody, in combination with chemotherapy in second-line or later treatment of patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The BLA submission was based on the overall results of the global Phase III HARMONi trial. The BLA was submitted during the fourth quarter of 2025.

“This BLA submission, the first for ivonescimab, marks a critical milestone for Summit, our global clinical development plan, and the many patients with EGFRm NSCLC in need of better therapeutics options,” stated Robert W. Duggan and Dr. Maky Zanganeh, Co-Chief Executive Officers of Summit. “As we continue to support and expand ivonescimab’s rapid development via our growing set of global Phase III trials and clinical collaborations, we look forward to the potential first U.S. approval for ivonescimab in this difficult to treat setting.”

HARMONi evaluated ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy in patients with EGFR-mutated, locally advanced or metastatic NSCLC who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor (TKI). This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials in showing either a progression-free survival (PFS) or overall survival (OS) benefit, the two primary endpoints of this clinical study.

Based upon standard review timelines, if the application is accepted as submitted, we anticipate a decision from the agency by the fourth quarter of 2026.

Update Regarding Current Financial Position

As of December 31, 2025, the company’s preliminary unaudited balance of cash, cash equivalents, and short-term investments was approximately $710 million. This amount is preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ from the amount that will be reflected in the Company’s consolidated financial statements for the year ended December 31, 2025.

About Ivonescimab

Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF.

This is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. We believe ivonescimab’s specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, SITC, 2023). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, SITC, 2023) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets.

Ivonescimab was engineered by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 4,000 patients have been treated with ivonescimab in clinical studies globally, and over 60,000 patients when considering those treated in a commercial setting in China, as noted by Akeso.

Summit began its clinical development of ivonescimab in NSCLC, commencing enrollment in 2023 in two multiregional Phase III clinical trials, HARMONi and HARMONi-3. In 2025, the Company began enrolling patients in HARMONi-7. Summit expanded its Phase III clinical development program into CRC in the fourth quarter of 2025 by initiating enrollment in HARMONi-GI3.

HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI (e.g., osimertinib). Detailed results of the study were provided in September 2025, and a Biologics License Application (BLA) was submitted to the United States Food and Drug Administration (FDA) for marketing authorization in the fourth quarter of 2025.

HARMONi-3 is a Phase III clinical trial, which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous or non-squamous NSCLC, irrespective of PD-L1 expression.

HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

HARMONi-GI3 is a Phase III clinical trial evaluating ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy in patients with first-line unresectable metastatic CRC.

In addition, Akeso has recently had positive read-outs in three single-region (China), randomized Phase III clinical trials, HARMONi-A, HARMONi-2, and HARMONi-6, for ivonescimab in NSCLC, including a statistically significant overall survival benefit in HARMONi-A with a manageable safety profile in each study.

HARMONi-A was a Phase III clinical trial which evaluated ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with an EGFR TKI.

HARMONi-2 is a Phase III clinical trial evaluating monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic NSCLC whose tumors have positive PD-L1 expression.

HARMONi-6 is a Phase III clinical trial evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous NSCLC, irrespective of PD-L1 expression.

Akeso is actively conducting multiple Phase III clinical studies in settings outside of NSCLC, including biliary tract cancer, colorectal cancer, breast cancer, pancreatic cancer, small cell lung cancer, and head and neck cancer.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.

About Summit Therapeutics

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol “SMMT”). We are headquartered in Miami, Florida, and we have additional offices in Menlo Park, California, and Oxford, UK.

For more information, please visit https://www.smmttx.com and follow us on X @SMMT_TX.

Summit Forward-looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc., the intended use of the net proceeds from the private placements, the Company’s anticipated spending and cash runway, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (“ATM Program”), the expected proceeds and uses thereof, the Company’s estimates regarding stock-based compensation, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a “positive study” as a clinical study that with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Summit Therapeutics and the Summit Therapeutics logo are trademarks of Summit Therapeutics Inc. and/or its affiliates

Copyright 2026, Summit Therapeutics Inc. All Rights Reserved

Contact Summit Investor Relations:

Dave Gancarz

Chief Business & Strategy Officer

Nathan LiaBraaten

Senior Director, Investor Relations

[email protected]

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Research Medical Devices FDA Clinical Trials Health Technology Biotechnology Pharmaceutical Health Science Oncology

MEDIA:

Logo
Logo
Posted on

QXO Upsizes Convertible Preferred Equity Placement to $3 Billion

QXO Upsizes Convertible Preferred Equity Placement to $3 Billion

Apollo and Temasek Lead Expanded Capital Commitment to Fund Future Acquisitions

GREENWICH, Conn.–(BUSINESS WIRE)–
QXO, Inc. (NYSE: QXO) (the “Company” or “QXO”) today announced a $1.8 billion increase to its previously announced $1.2 billion financing led by funds managed by affiliates of Apollo Global Management, Inc. (NYSE: APO) (“Apollo”), bringing the total investment in QXO to $3 billion. Apollo, Temasek, and certain other investors have agreed to make the investment through the previously disclosed series of convertible perpetual preferred stock (the “Series C Preferred Stock”). The investment further strengthens QXO’s financial flexibility to pursue strategic acquisition opportunities.

Under the investment agreement, the investors have committed to purchase Series C Preferred Stock to fund one or more qualifying acquisitions through July 15, 2026. This commitment will be extended for up to an additional 12 months if a definitive acquisition agreement is executed before the initial commitment period expires. Any issuance of the Series C Preferred Stock will close at or around the closing of the qualifying acquisition(s).

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be reoffered or resold in the United States except through an effective registration statement or an applicable exemption from the registration requirements. The Company has agreed to use commercially reasonable efforts to file a prospectus supplement with the Securities and Exchange Commission (“SEC”) to register the resale of the Series C Preferred Stock and underlying common stock issuable upon conversion.

This press release is issued pursuant to Rule 135c under the Securities Act and does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About QXO

QXO is the largest publicly traded distributor of roofing, waterproofing, and complementary building products in North America. The company plans to become the tech-enabled leader in the $800 billion building products distribution industry and generate outsized value for shareholders. QXO is targeting $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth. Visit QXO.com for more information.

About Apollo

Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative, and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees, and the communities we impact, to expand opportunity and achieve positive outcomes. As of September 30, 2025, Apollo had approximately $908 billion of assets under management. To learn more, please visit www.apollo.com.

About Temasek

Temasek is a global investment company headquartered in Singapore, with a net portfolio value of S$434 billion (US$324 billion) as at 31 March 2025. Its Purpose “So Every Generation Prospers” guides it to make a difference for today’s and future generations. Temasek seeks to build a resilient and forward-looking portfolio that will deliver sustainable returns over the long term. It has 13 offices in 9 countries around the world: Beijing, Hanoi, Mumbai, Shanghai, Shenzhen, and Singapore in Asia; and Brussels, London, Mexico City, New York, Paris, San Francisco, and Washington, DC outside Asia. For more information on Temasek, please visit www.temasek.com.sg.

Forward-looking statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact, including statements with respect to the issuance of the Series C Preferred Stock and the terms thereof, are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “trajectory” or the negative of these terms or other comparable terms. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances.

These forward-looking statements are subject to known and unknown risks, uncertainties, and assumptions that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause or contribute to a material difference include the risks discussed in our filings with the SEC, and the following:

  • an inability to obtain the products we distribute, resulting in lost revenues and reduced margins and damaging our relationships with customers;

  • a change in supplier pricing and demand, which may adversely affect our income and gross margins;

  • a change in vendor rebates, which may adversely affect our income and gross margins;

  • our inability to identify potential acquisition targets or successfully complete acquisitions on acceptable terms;

  • risks related to maintaining our safety record;

  • the possibility that building products distribution industry demand may soften or shift substantially due to cyclicality or dependence on general economic and political conditions, including inflation or deflation, interest rates, governmental subsidies or incentives, consumer confidence, labor and supply shortages, weather and commodity prices;

  • the possibility that regional, national or global barriers to trade, including trade wars, could increase the cost of products in the building products distribution industry, which could adversely impact the competitiveness of such products and the financial results of businesses in the industry;

  • seasonality, weather-related conditions and natural disasters;

  • risks related to the proper functioning of our information technology systems, including threats related to cybersecurity and artificial intelligence;

  • loss of key talent or our inability to attract and retain new qualified talent;

  • risks related to work stoppages, union negotiations, labor disputes and other matters associated with our labor force or the labor forces of our suppliers or customers;

  • the risk that the anticipated benefits of our acquisition of Beacon Roofing Supply, Inc. (the “Beacon Acquisition”) or any future acquisition may not be fully realized or may take longer to realize than expected;

  • the effect of the Beacon Acquisition or any future acquisition on our business relationships with employees, customers or suppliers, operating results and the business generally;

  • unexpected liabilities, costs, charges, expenses or accounting adjustments resulting from the Beacon Acquisition or any future acquisition or difficulties in integrating and operating acquired companies;

  • risks related to the Company’s obligations under the indebtedness incurred in connection with the Beacon Acquisition;

  • the risk that the Company is or becomes highly dependent on the continued leadership of Brad Jacobs as chairman and chief executive officer and the possibility that the loss of Mr. Jacobs in these roles could have a material adverse effect on the Company’s business, financial condition and results of operations;

  • the possible economic impact of the Company’s outstanding warrants and preferred stock on the Company and the holders of its common stock, including market price volatility, dilution from the exercise or conversion of the warrants or preferred stock, or the impact of dividend payments from preferred stock that remains outstanding;

  • challenges in raising additional equity or debt capital from public or private markets to pursue the Company’s business plan and the effects that raising such capital may have on the Company and its business;

  • the possibility that new investors in any future financing transactions could gain rights, preferences and privileges senior to those of the Company’s existing stockholders;

  • risks associated with periodic litigation, regulatory proceedings and enforcement actions, which may adversely affect the Company’s business and financial performance;

  • the impact of legislative, regulatory, economic, competitive and technological changes;

  • unknown liabilities and uncertainties regarding general economic, business, competitive, legal, regulatory, tax and geopolitical conditions; and

  • other factors, including those set forth in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q.

All forward-looking statements set forth in this release are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences for or effects on us or our business or operations. Forward-looking statements set forth in this release speak only as of the date hereof, and we do not undertake any obligation to update forward-looking statements except to the extent required by law.

QXO Contacts:

Media

Joe Checkler

[email protected]

203-609-9650

Investors

Mark Manduca

[email protected]

203-321-3889

Apollo Contacts:

Media

Joanna Rose

[email protected]

212-822-0491

Investors

Noah Gunn

[email protected]

212-822-0540

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Residential Building & Real Estate Building Systems Commercial Building & Real Estate Construction & Property Finance Professional Services Trucking Asset Management Transport Urban Planning REIT Interior Design Logistics/Supply Chain Management Architecture Other Construction & Property

MEDIA:

Logo
Logo
Posted on

Rockwell Medical Adds 30 New Customers in the West

Rockwell Medical Adds 30 New Customers in the West

The Company generates multi-million dollars in revenue with new west coast customer base

The Western U.S. now accounts for more than 10% of the Company’s customer clinic footprint

WIXOM, Mich.–(BUSINESS WIRE)–
Rockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has added 30 new customers in the western portion of the United States.

“Over the past several months, the hemodialysis concentrates supply chain has experienced meaningful disruption, particularly in the western United States,” said Mark Strobeck, Ph.D., President and CEO of Rockwell Medical. “Historically, hemodialysis concentrates supplier options in the west have been extremely limited. To stabilize the supply chain and ensure uninterrupted access to life-sustaining treatments for vulnerable patients with end-stage kidney disease, Rockwell Medical moved quickly to ensure product availability by rapidly scaling production and expanding our logistics infrastructure to address vital customer demand. As a result, we are now serving customers across the continental United States with our reliable supply chain and high-quality hemodialysis products.”

The Company’s new customer base includes, but is not limited to, a large, integrated, non-profit healthcare system; a comprehensive chronic kidney disease and dialysis care organization serving patients throughout California; a community-based, non-profit acute care hospital; and an innovation-driven renal care center developing and delivering next-generation artificial kidney solutions. With its expanded distribution capabilities, Rockwell Medical is now a viable alternative supplier in the western United States and is able to more efficiently deliver hemodialysis concentrates products to its existing customers with facilities in that region.

About Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical’s mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. Rockwell Medical’s products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & Production™ in 2024 and 2025, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions™. For more information, visit www.rockwellmed.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as, “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “can,” “would,” “develop,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend,” “look forward to,” “remain confident,” “are determined,” “are committed to,” “are on track,” “are resolute in our vision,” “work to,” “drive towards,” “focused on,” “seeks to” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical’s SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2024, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

(248) 432-1362

[email protected]

KEYWORDS: Michigan United States North America

INDUSTRY KEYWORDS: Other Manufacturing Medical Devices Medical Supplies Transport Manufacturing Other Health Health General Health Logistics/Supply Chain Management

MEDIA:

Logo
Logo
Posted on

Savers Value Village, Inc. Announces Preliminary Fourth Quarter and Full Year Net Sales and Participation in the 28th Annual ICR Conference

Savers Value Village, Inc. Announces Preliminary Fourth Quarter and Full Year Net Sales and Participation in the 28th Annual ICR Conference

BELLEVUE, Wash.–(BUSINESS WIRE)–
Savers Value Village, Inc. (NYSE: SVV), (the “Company”) today announced preliminary net sales for the fourteen weeks ended January 3, 2026 (the “fourth quarter”) and the fifty-three weeks ended January 3, 2026 (“fiscal 2025”) in conjunction with the Company’s participation in the ICR Conference January 12-14, 2026. The Company’s results for both the fourth quarter and full year ended January 3, 2026 included the benefit of one additional week (the “53rd week”) relative to the prior year comparative periods.

The Company reported the following results on a preliminary and unaudited basis.

Fourth Quarter1:

  • Total Company net sales increased 15.6% to $464.7 million. Excluding the benefit of the 53rd week, net sales increased 8.4%, constant-currency net sales2 increased 8.4% and comparable store sales increased 5.4%.

  • For the United States (“U.S.”), net sales increased 20.6%. Excluding the benefit of the 53rd week, net sales increased 12.6% and comparable store sales increased 8.8%.

  • For Canada, net sales increased 9.1%. Excluding the benefit of the 53rd week, net sales increased 3.1%, constant-currency net sales2 increased 3.0% and comparable store sales increased 0.7%.

Fiscal 20251:

  • Total Company net sales increased 9.2% to $1.68 billion. Excluding the benefit of the 53rd week, net sales increased 7.3%, constant-currency net sales2 increased 8.2% and comparable store sales increased 4.7%.

  • For the U.S., net sales increased 12.9%. Excluding the benefit of the 53rd week, net sales increased 10.8% and comparable store sales increased 6.6%.

  • For Canada, net sales increased 3.6%. Excluding the benefit of the 53rd week, net sales increased 2.0%, constant-currency net sales2 increased 4.1% and comparable store sales increased 2.0%.

Mark Walsh, Chief Executive Officer of Savers Value Village, Inc. commented, “We are very pleased with our 5.4% fourth quarter comparable store sales, particularly 8.8% U.S. comparable store sales, our primary growth market. This strength underscores that our sharp value and great selection continue to resonate with consumers.”

Fiscal 2025 Outlook

Based on the preliminary fourth quarter and fiscal 2025 net sales results outlined above, the Company reaffirms its previously provided fiscal 2025 Adjusted Net Income3 outlook of approximately $71 million to $75 million, or $0.44 to $0.46 per diluted share, and Adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”)3 outlook of approximately $252 million to $257 million.

1 Comparisons are to the prior year comparative period.

2 Amounts presented on a constant currency basis are not measures recognized under U.S. generally accepted accounting principles (“GAAP”). For additional information on our use of non-GAAP financial measures, see “Non-GAAP Financial Measures” below.

3 The fiscal 2025 outlook is provided on a non-GAAP basis as the Company cannot predict certain elements that are reported under GAAP, such as (gains) losses on foreign currency, net. For additional information on our use of non-GAAP financial measures, see “Non-GAAP Financial Measures” below.

Capital Allocation

Consistent with its capital allocation strategy, during the fourth quarter the Company repaid $20 million of principal under its 2025 term loan facility and repurchased approximately 1.1 million shares of its common stock at a weighted average price of $8.75, excluding commissions, pursuant to its share repurchase programs. As of the end of the fourth quarter, the Company had approximately $41.7 million remaining under its share repurchase program.

Participation in the ICR Conference

The Company also announced its participation in the 28th Annual ICR Conference in Orlando, Florida January 12-14, 2026. Mark Walsh, CEO, Jubran Tanious, COO and President, Michael Maher, CFO and Treasurer, and Ed Yruma, VP Investor Relations and Treasury, will meet with investors and deliver a presentation at 8:00 am Eastern Standard Time on Monday, January 12, 2026. The live webcast will be available in listen-only mode at https://event.summitcast.com/view/GC3Lpwomn4ZmhBu9nkP7aE/GBXHSHUBM6oxxyRvfxhRME. An archived replay of the webcast will be available following the event in the Investor Relations section of the Company’s website at https://ir.savers.com.

About the Savers Value Village™ family of thrift stores

As the largest for-profit thrift operator in the U.S. and Canada for value priced pre-owned clothing, accessories and household goods, our mission is to champion reuse and inspire a future where secondhand is second nature. Learn more about the Savers Value Village family of thrift stores, our impact, and the #ThriftProud movement at savers.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” or the negative of these terms or other comparable terminology. In particular, statements about future events and similar references to future periods, or by the inclusion of forecasts or projections, the outlook for the Company’s future business, prospects, financial performance, including its outlook or financial guidance, and industry outlook are forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, the Company’s actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: the impact on both the supply and demand for the Company’s products caused by general economic conditions, such as the macroeconomic pressures in Canada and/or the U.S., and changes in consumer confidence and spending; the Company’s ability to anticipate consumer demand and to source and process a sufficient quantity of quality secondhand items at attractive prices on a recurring basis; risks related to attracting new, and retaining existing customers, including by increasing acceptance of secondhand items among new and growing customer demographics; risks associated with its status as a “brick and mortar” only retailer and its lack of operations in the growing online retail marketplace; its failure to open new profitable stores, or successfully enter new markets on a timely basis or at all; the risks associated with conducting business internationally, including challenges related to serving customers that are international manufacturers and suppliers, such as transportation and shipping challenges, regulatory risks in foreign jurisdictions (particularly in Canada, where the Company maintains extensive operations) and exchange rate risks, which the Company may not choose to fully hedge; the loss of, or disruption or interruption in the operations of, its centralized processing centers and other offsite processing locations; risks associated with litigation, the expense of defense, and the potential for adverse outcomes; its failure to properly hire and to retain key personnel and other qualified personnel or to manage labor costs; risks associated with the timely and effective deployment, protection, and defense of computer networks and other electronic systems, including e-mail; changes in government regulations, procedures and requirements; its ability to maintain an effective system of internal controls and produce timely and accurate financial statements or comply with applicable regulations; risks associated with heightened geopolitical instability due to the conflicts in Venezuela, the Middle East and Eastern Europe; outbreak of viruses or widespread illness, such as the COVID-19 pandemic, natural disasters or other highly disruptive events and regulatory responses thereto; and each of the other factors set forth under the heading “Risk Factors” in its filings with the United States Securities and Exchange Commission. Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company is not under any obligation (and specifically disclaims any such obligation) to update or alter these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Non-GAAP Financial Measures

The Company reports its financial results in accordance with GAAP. Non-GAAP financial measures used by the Company include Adjusted net income, Adjusted net income per diluted share and Adjusted EBITDA. The Company has included these non-GAAP financial measures in this press release as they are key measures used by its management and its board of directors to evaluate its operating performance and the effectiveness of its business strategies, make budgeting decisions, and evaluate compensation decisions. Adjusted net income, Adjusted net income per diluted share and Adjusted EBITDA are not calculated or presented in accordance with GAAP and have limitations as analytical tools. You should not consider them in isolation, as a substitute for, or superior to, analysis of the Company’s results as reported under GAAP. There are limitations to using non-GAAP financial measures, including those amounts presented in accordance with the Company’s definitions of Adjusted net income, Adjusted net income per diluted share and Adjusted EBITDA, as they may not be comparable to similar measures disclosed by the Company’s competitors, because not all companies and analysts calculate Adjusted net income, Adjusted net income per diluted share and Adjusted EBITDA in the same manner. Because of these limitations, you should consider Adjusted net income, Adjusted net income per diluted share and Adjusted EBITDA alongside other financial performance measures, including, as applicable, net income, net income per diluted share and the Company’s other GAAP results. The Company presents Adjusted net income, Adjusted net income per diluted share and Adjusted EBITDA because it considers these meaningful measures to share with investors as they best allow comparison of the performance of one period with that of another period. In addition, by presenting Adjusted net income, Adjusted net income per diluted share and Adjusted EBITDA, the Company provides investors with management’s perspective of the Company’s operating performance.

The Company defines Adjusted net income as net income excluding the impact of loss on extinguishment of debt, IPO-related stock-based compensation expense, transaction costs, foreign currency exchange rate impacts, certain other adjustments, the tax effect on the above adjustments and the excess tax shortfall from stock-based compensation. The Company defines Adjusted net income per diluted share as Adjusted net income divided by diluted weighted average common shares outstanding.

The Company defines Adjusted EBITDA as net income excluding the impact of interest expense, net, income tax expense, depreciation and amortization, loss on extinguishment of debt, stock-based compensation expense, lease intangible asset expense, transaction costs, foreign currency exchange rate impacts and certain other adjustments.

The Company reports certain operating results on a constant-currency basis in order to facilitate period-to-period comparisons of its results without regard to the impact of fluctuating foreign currency exchange rates. The term foreign currency exchange rates refers to the exchange rates used to translate the Company’s operating results for all countries where the functional currency is not the U.S. Dollar (“USD”) into USD. Because the Company is a global company, foreign currency exchange rates used for translation may have a significant effect on its reported results. In general, given the Company’s significant operations in Canada, the Company’s financial results are affected positively by a weakening of the USD against the Canadian Dollar (“CAD”) and are affected negatively by a strengthening of the USD against the CAD. References to operating results on a constant-currency basis indicate operating results without the impact of foreign currency exchange rate fluctuations.

The Company believes disclosure of constant-currency net sales is helpful to investors because it facilitates period-to-period comparisons of its results by increasing the transparency of its underlying performance by excluding the impact of fluctuating foreign currency exchange rates. However, constant-currency results are not calculated or presented in accordance with GAAP and are not meant to be considered as an alternative or substitute for, or superior to, comparable measures prepared in accordance with GAAP. Constant-currency results have no standardized meaning prescribed by GAAP, are not prepared under any comprehensive set of accounting rules or principles and should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP.

Constant-currency results have limitations in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. During the fourteen weeks ended January 3, 2026, as compared to the thirteen weeks ended December 28, 2024, the USD was weaker relative to the CAD and the Australian dollar (“AUD”) which resulted in a favorable foreign currency impact on our operating results. During the fifty-three weeks ended January 3, 2026, as compared to the fifty-two weeks ended December 28, 2024, the USD was stronger relative to the CAD and the AUD which resulted in an unfavorable foreign currency impact on our operating results. The Company calculates constant-currency net sales by translating current period net sales using the average exchange rates from the comparative prior period rather than the actual average exchange rates in effect.

Constant Currency

The Company calculates constant-currency net sales by translating current-period net sales using the average exchange rates from the comparative prior period rather than the actual average exchange rates in effect. The Company’s constant-currency net sales is not a financial measure prepared in accordance with GAAP.

The following unaudited table presents a reconciliation of GAAP net sales to constant-currency net sales, excluding the benefit of the 53rd week, for the periods presented. In each table, “Other” is attributable to the Australia Retail and Wholesale operating segments which have been combined.

(dollars in thousands)

Net Sales

 

Benefit of 53rd Week

 

Impact of Foreign Currency

 

Constant-Currency Net Sales

 

$ Change Over Prior Year

 

% Change Over Prior Year

Fourteen Weeks Ended January 3, 2026

 

 

 

 

 

 

 

 

 

 

 

U.S. Retail

$

265,875

 

$

(17,552

)

 

$

—

 

 

$

248,323

 

$

27,860

 

12.6

%

Canada Retail

 

164,894

 

 

(9,150

)

 

 

(100

)

 

 

155,644

 

 

4,514

 

3.0

%

Other

 

33,897

 

 

(2,221

)

 

 

(50

)

 

 

31,626

 

 

1,234

 

4.1

%

Total net sales

$

464,666

 

$

(28,923

)

 

$

(150

)

 

$

435,593

 

$

33,608

 

8.4

%

Thirteen Weeks Ended December 28, 2024

 

 

 

 

 

 

 

 

 

 

 

U.S. Retail

$

220,463

 

 

n/a

 

 

 

n/a

 

 

$

220,463

 

 

n/a

 

n/a

 

Canada Retail

 

151,130

 

 

n/a

 

 

 

n/a

 

 

 

151,130

 

 

n/a

 

n/a

 

Other

 

30,392

 

 

n/a

 

 

 

n/a

 

 

 

30,392

 

 

n/a

 

n/a

 

Total net sales

$

401,985

 

 

n/a

 

 

 

n/a

 

 

$

401,985

 

 

n/a

 

n/a

 

(dollars in thousands)

Net Sales

 

Benefit of 53rd Week

 

Impact of Foreign Currency

 

Constant-Currency Net Sales

 

$ Change Over Prior Year

 

% Change Over Prior Year

Fifty-Three Weeks Ended January 3, 2026

 

 

 

 

 

 

 

 

 

 

 

U.S. Retail

$

940,185

 

$

(17,552

)

 

$

—

 

$

922,633

 

$

90,052

 

10.8

%

Canada Retail

 

608,093

 

 

(9,150

)

 

 

12,287

 

 

611,230

 

 

24,259

 

4.1

%

Other

 

130,676

 

 

(2,221

)

 

 

1,412

 

 

129,867

 

 

11,802

 

10.0

%

Total net sales

$

1,678,954

 

$

(28,923

)

 

$

13,699

 

$

1,663,730

 

$

126,113

 

8.2

%

Fifty-Two Weeks Ended December 28, 2024

 

 

 

 

 

 

 

 

 

 

 

U.S. Retail

$

832,581

 

 

n/a

 

 

 

n/a

 

$

832,581

 

 

n/a

 

n/a

 

Canada Retail

 

586,971

 

 

n/a

 

 

 

n/a

 

 

586,971

 

 

n/a

 

n/a

 

Other

 

118,065

 

 

n/a

 

 

 

n/a

 

 

118,065

 

 

n/a

 

n/a

 

Total net sales

$

1,537,617

 

 

n/a

 

 

 

n/a

 

$

1,537,617

 

 

n/a

 

n/a

 

n/a – not applicable

 

Investor Contact:

Ed Yruma

[email protected]

Media Contact:

Edelman Smithfield | 713.299.4115 | [email protected]

Savers | 206.228.2261 | [email protected]

KEYWORDS: Florida Washington United States North America

INDUSTRY KEYWORDS: Retail Discount/Variety Department Stores Fashion

MEDIA:

Logo
Logo
Posted on

NUTEX HEALTH RE-OPENS BAYOU CITY ER & HOSPITAL IN HOUSTON

PR Newswire

HOUSTON, Jan. 12, 2026 /PRNewswire/ — Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced the reopening of Bayou City ER & Hospital, located northeast of Houston at 19211 McKay Dr., Humble, Texas.

The staff of medical experts at Bayou City ER & Hospital are bringing the community 24/7/365 days of concierge-level care. The 40,000 square foot state-of-the-art facility houses 8 Emergency Room beds and 46 inpatient beds. It features a full-service laboratory and advanced imaging technology, including CT, X-ray, and ultrasound, with same-day scheduling and rapid results.

Laura Rodriguez, FACHE, RN, MBA, MHA, CNAA-BC, chief administrative officer and chief nursing officer of Bayou City ER & Hospital, said the opening marks the culmination of an extensive transformation process.

“With opening day finally here, the excitement surrounding Bayou City ER and Hospital is difficult to put into words. Today, the facility stands as a beautiful, state-of-the-art building ready to serve the community. Bayou City ER and Hospital is delighted to open its doors and become a trusted healthcare partner for the community—delivering compassionate care, advanced medical services, and a welcoming environment from day one,” stated Rodriguez.

Tom Vo, M.D., MBA, chairman and CEO of Nutex Health, said the reopening of Nutex’s largest hospital represents a significant milestone for the company and reinforces its commitment to the Humble and Kingwood areas. He emphasized the growing need for access to high-quality care close to home in Northeast Houston.

“Our vision is to transform healthcare delivery by providing specialized services for patients with unique needs—such as behavioral health, medical detox, and other challenging conditions—which traditional systems struggle to treat efficiently,” stated Vo. “By expanding these critical resources, we aim to not only improve individual lives but also strengthen the overall health and resilience of the community.”

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 27 facilities in 12 states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations. Through our Management Services Organization, we provide management, administrative and other support services to our affiliated hospitals and physician groups.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words or phrases “will,” “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, to remediate our material weaknesses in a timely manner, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025, under the heading “Risk Factors” in Part II, Item IA thereof, and the risk factors and other cautionary statements contained in our other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Cision View original content:https://www.prnewswire.com/news-releases/nutex-health-re-opens-bayou-city-er–hospital-in-houston-302658194.html

SOURCE Nutex Health, Inc.

Posted on

TAL Education Group to Announce Third Quarter of Fiscal Year 2026 Financial Results on January 29, 2026

PR Newswire

BEIJING, Jan. 12, 2026 /PRNewswire/ — TAL Education Group (“TAL” or the “Company”) (NYSE: TAL), a smart learning solutions provider in China, today announced that it will release its unaudited financial results for the third quarter of fiscal year 2026 ended November 30, 2025,  before the market opens on Thursday, January 29, 2026.

The Company will host a corresponding conference call and live webcast at 7:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing Time) on Thursday, January 29, 2026.

Please note that you will need to pre-register for conference call participation at 

https://dpregister.com/sreg/10205339/102f9a80ea5.

Upon registration, you will receive an email containing participant dial-in numbers, passcode, and a unique access PIN. This information will allow you to gain immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

A replay of the conference call will be available by phone at the numbers listed below, starting one hour after the live call concludes and remaining accessible through February 5, 2026:

United States:

1-855-669-9658

International:

1-412-317-0088

Passcode:

8751787

A live and archived webcast of the conference call will be available on the Investor Relations section of TAL’s website at https://ir.100tal.com/.

About TAL Education Group

TAL Education Group is a smart learning solutions provider in China. The acronym “TAL” stands for “Tomorrow Advancing Life”, which reflects our vision to promote top learning opportunities for students through both high-quality teaching and content, as well as leading edge application of technology in the education experience. TAL Education Group offers comprehensive learning solutions to students from all ages through diversified class formats. Our learning solutions mainly cover enrichment learnings programs and some academic subjects in and out of China. Our ADSs trade on the New York Stock Exchange under the symbol “TAL”.

For investor and media inquiries, please contact:

In China:

Jackson Ding
Investor Relations
TAL Education Group
Tel: +86 10 5292 6669-8809
Email: [email protected]

Christensen Advisory
Tel: +86 10 5900 1548
Email: [email protected]

 

Cision View original content:https://www.prnewswire.com/news-releases/tal-education-group-to-announce-third-quarter-of-fiscal-year-2026-financial-results-on-january-29-2026-302658346.html

SOURCE TAL Education Group

Posted on

XPENG Charts New Course in 2026: Flagship Launch, Sales Momentum, and AI Breakthrough Propel Global Technology Ambitions

PR Newswire

GUANGZHOU, China, Jan. 12, 2026 /PRNewswire/ — XPENG is ushering in 2026 with transformative momentum, reinforcing its strategic evolution into an AI-driven global technology leader. The company unveiled its next-generation flagship model, celebrated a critical production milestone, and introduced a revolutionary autonomous driving AI system, collectively marking a significant leap forward in intelligent mobility.


XPENG Spring Product Launch Event – Press Kit


XPENG at the Brussels Motor Show – Press Kit

Global Product Expansion and Sustained Market Growth

On January 8, XPENG officially launched the 2026 XPENG P7+ at its 2026 Spring Product Launch Event in Guangzhou. The new P7+, a premium AI-powered sedan available in both Super Extended-Range and all-electric configurations, is set for simultaneous rollout across 36 countries. Its pure-electric variant made its European debut at the Brussels Motor Show on January 9, where the XPENG P7+ also demonstrated its impressive cargo capacity on stage, as 33 pieces of 20-inch luggage were smoothly extracted from its spacious sedan interior.

Engineered to global standards in R&D, manufacturing, and quality, the 2026 P7+ delivers 104 experience enhancements and a 36% renewal rate of core assembly components. Notably, the model has successfully completed trial production at the plant of XPENG’s manufacturing partner Magna in Graz, Austria, underscoring the company’s global operational readiness.

This product offensive is bolstered by exceptional commercial traction. In 2025, XPENG achieved global deliveries of 429,445 vehicles, representing a remarkable 126% year-over-year growth. International markets were a standout contributor, with overseas deliveries surging 96% to 45,008 units. Momentum in Europe was particularly strong, where deliveries soared 126% to 22,787 units. XPENG’s presence now spans 60 countries and regions, with the brand consistently ranking as the top-selling Chinese EV startup in key European markets, including Belgium, Norway, and France.

AI Breakthrough: Introducing the Next-Generation VLA

Central to XPENG’s technology vision is the in-house developed second-generation Visual-Language-Action (VLA 2.0) model, hailed as the industry’s first physical-AI system with foundational L4 autonomous driving capabilities. This innovation represents a paradigm shift by removing the conventional “language translation” intermediary, enabling end-to-end generation of driving commands directly from visual inputs. This architecture allows AI to interpret and interact with the real world more naturally and efficiently. The same VLA2.0 foundation powers XPENG’s Robotaxi, which has already passed third-party closed-track testing and is preparing for public road trials. The VLA2.0 is scheduled to begin over-the-air deployment to customer vehicles starting March 2026.

A Milestone of Scale and Trust: 100,000th P7+ Produced

Marking a significant production achievement, the 100,000th XPENG P7+ rolled off the assembly line in Guangzhou on January 9. Chairman and CEO He Xiaopeng commemorated the milestone, stating, “This is more than a numerical achievement – it is a powerful validation of our technological progress and, most importantly, of the trust our users have placed in us.” A dedicated owner delivery ceremony accompanied the celebration, highlighting the brand’s focus on harmonizing advanced technology with human-centric engagement.

Moving Forward as a Global Technology Leader

The concurrent announcements of a globally launched flagship, record-setting international growth, a foundational AI advancement, and a key manufacturing milestone collectively signal XPENG’s accelerated transition from an automaker to a technology architect. By leveraging its integrated, AI-defined software and hardware stack, XPENG is advancing beyond conventional automotive competition, positioning itself as a distinct and forward-looking leader in the next era of intelligent mobility worldwide.

About XPENG

XPENG is committed to leading the transformation of future mobility through technological exploration, positioning itself as “Explorer of Future Mobility”. Headquartered in Guangzhou, China, the company operates R&D centers in Beijing, Shanghai, Shenzhen, Zhaoqing, and Yangzhou, and has established intelligent manufacturing bases in Zhaoqing and Guangzhou.

XPENG pursues a global strategy for research, development, and sales, with an R&D center in the United States and subsidiaries across multiple European countries. The company adheres to full-stack in-house development of intelligent driver-assistance software and the development of core hardware, delivering an exceptional intelligent driving and riding experience for users.

On August 27, 2020, XPENG officially listed on the New York Stock Exchange (NYSE: XPEV), raising funds in an IPO that set a record at the time for the global new energy vehicle industry. On July 7, 2021, the company listed on the Hong Kong Stock Exchange (HKEX: 9868), becoming the first Chinese new-energy automaker to achieve dual primary listings in both Hong Kong and New York.

For more information, please visit https://www.xpeng.com/.

Contacts: 

For Media Enquiries: Sarah Cheng, XPENG PR Department
Email: [email protected] 

 

Cision View original content:https://www.prnewswire.com/news-releases/xpeng-charts-new-course-in-2026-flagship-launch-sales-momentum-and-ai-breakthrough-propel-global-technology-ambitions-302658303.html

SOURCE XPENG

Posted on

AIxCrypto Launches AIxC Hub Ecosystem Platform; Inaugural S1 Arena Attracts Over 200,000 Participants in Five Days

PR Newswire

LOS ANGELES, Jan. 12, 2026 /PRNewswire/ — AIxCrypto Inc. (NASDAQ: AIXC) announced the official launch of AIxC Hub, its core ecosystem engagement platform, and released initial operational metrics from its inaugural competitive season, S1 Arena. Since its launch on January 7, the platform, serving as the primary user gateway to the AIxC ecosystem, has attracted over 200,000 registered wallet addresses (participants), reflecting strong early user adoption.

AIxC Hub: Ecosystem Engagement and Education Platform

AIxC Hub is the core interactive platform of the AIxCrypto ecosystem, designed to introduce users to the fundamentals of Real World Asset (RWA) tokenization and Embodied AI (EAI) application logic through a structured, gamified participation model.

The platform operates on a season-based framework, with each season featuring distinct themes, tasks, and competitive mechanics. Users accumulate points through participation, compete on leaderboards, and progressively gain exposure to AIxCrypto’s strategic positioning and product architecture.

All activities, points, rankings, and rewards are calculated and settled on a per-season basis. Users may earn additional point multipliers by linking verified social media accounts, including X (formerly Twitter) and Discord, and by participating in community discussions, official AMAs, and other engagement activities.

S1 Arena: Inaugural Prediction-Based Competitive Season

As the first competitive season of AIxC Hub, S1 Arena focuses on market simulation and education. Users accumulate points by submitting directional predictions on the C10 Index, AIxCrypto’s crypto asset basket index. Correct predictions generate point rewards, while incorrect predictions carry no point penalty. This zero-capital simulation framework is designed to lower barriers to entry and allow users to explore RWA-related trading logic and market analysis in a risk-controlled environment.

S1 Arena offers two participation modes: individual and faction-based. In faction mode, users may form or join teams to receive point multipliers, cooperative bonuses, and team-based rankings, which contribute to season-wide recognition and outcomes.

Early Adoption Metrics

As of January 11, within approximately 5 days of launch, S1 Arena recorded the following metrics:

– 200,156 registered wallet addresses (participants)

– 163,762 active participants earning points

– 58,082 verified social media accounts

  • X (formerly Twitter): 22,641;
  • Discord: 25,826;
  • Telegram: 9,615

– 22,908 community interactions on X (formerly Twitter) associated with AIxC ecosystem accounts

During the initial launch period, AIxC-related content generated more than 3 million social media impressions within 48 hours, alongside approximately 8,000 likes, 7,000 comments to such content; and 6,400 new followers to AIxC ecosystem X accounts.

Based on statistics provided by XHunt, both AIxC’s official X account and the AIxC Foundation X account ranked among the top two trending crypto projects in crypto-related X (formerly Twitter) discussions during the initial launch period.

Through strategic engagement with more than 160 key opinion leaders (KOLs) representing a combined audience of over 8 million followers, AIxCrypto has established early community presence across Vietnam, Korea, and China, with additional market expansion planned for Brazil and Europe.

Upcoming Developments

Upon the conclusion of S1 Arena, AIxCrypto plans to host a Global Summit in Los Angeles, where top-ranked participants will be invited to attend an on-site recognition ceremony and industry networking event.

Future seasons of AIxC Hub are expected to introduce expanded prediction categories linked to AIxCrypto’s RWA tokenization initiatives, deeper integration with BesTrade, the company’s AI-powered decentralized trading platform, and broader cross-chain participation enabled through multi-chain wallet support.

To explore AIxC Hub, visit:
https://hub.aixcrypto.ai

To explore AIxC S1 Arena gameplay and season rules, visit:
https://aixc.gitbook.io/aixc-hub-docs-en/

About AIxCrypto:  

AIxCrypto is a U.S.-Nasdaq listed company dedicated to building a world-leading ecosystem that integrates AI and blockchain while bridging Web2 and Web3. Its core products include the BesTrade DeAI Agent and the AIxC ecosystem products.  

FORWARD LOOKING STATEMENTS: 

This press release contains “forward-looking statements”, including statements regarding AIxCrypto Holdings, Inc. (“AIxCrypto”) within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All of the statements in this press release, including financial projections, whether written or oral, that refer to expected or anticipated future actions and results of AIxCrypto are forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements reflect our current projections and expectations about future events as of the date of this presentation. AIxCrypto cannot give any assurance that such forward-looking statements and financial projections will prove to be correct.  

The information provided in this press release does not identify or include any risk or exposures of AIxCrypto that would materially and adversely affect the performance or risk of the company. By their nature, forward-looking statements and financial projections involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking information will not occur, which may cause the Company’s actual performance and financial results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements and financial projections. Important factors that could cause actual results to differ materially from expectations include, but are not limited to: business, economic and capital market conditions; the heavily regulated industry in which AIxCrypto carries on business; current or future laws or regulations and new interpretations of existing laws or regulations; the inherent volatility and regulatory uncertainty associated with cryptocurrency investments; legal and regulatory requirements; market conditions and the demand and pricing for our products; the availability of reaching an agreement for the purchase of FFAI common shares; our relationships with our customers and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers’ needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; failure of counterparties to perform their contractual obligations; systems, networks, telecommunications or service disruptions or failures or cyber-attack; ability to obtain additional financing on reasonable terms or at all; litigation costs and outcomes; our ability to successfully maintain and enforce our intellectual property rights and defend third party claims of infringement of their intellectual property rights; and our ability to manage our growth. Readers are cautioned that this list of factors should not be construed as exhaustive.  

All information contained in this press release is provided as of the date of the press release issuance and is subject to change without notice. Neither AIxCrypto, nor any other person undertakes any obligation to update or revise publicly any of the forward-looking statements and financial projections set out herein, whether as a result of new information, future events or otherwise, except as required by law. This is presented as a source of information and not an investment recommendation. This press release does not take into account nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. AIxCrypto reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or to notify the recipient thereof.  

Readers are advised not to place undue reliance on forward-looking statements, as there is no guarantee that the plans, intentions, or expectations they are based on will be realized. While management believes these statements are reasonable at the time of preparation, actual results may differ materially. These forward-looking statements reflect the Company’s expectations as of the date of this presentation and are subject to change without notice. The Company is not obligated to update or revise these statements, unless required by law.  

Forward-looking statements are often identified by words such as “may,” “could,” “would,” “might,” or “will,” indicating possible future actions, events, or outcomes. These statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ significantly from what is expected.   

Actual results may differ materially due to factors such as the ability to secure financing, complete transactions, meet exchange requirements, consumer demand, competition, and unexpected costs. These forward-looking statements are based on assumptions that may prove incorrect, and the Company does not assume any obligation to update them except as required by law. Given the uncertainties involved, readers should not place undue reliance on these statements.  

You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  

Cision View original content:https://www.prnewswire.com/news-releases/aixcrypto-launches-aixc-hub-ecosystem-platform-inaugural-s1-arena-attracts-over-200-000-participants-in-five-days-302658289.html

SOURCE AIxCrypto Inc.

Posted on

Energy Leaders Abunayyan Holding and Nextpower Complete Formation of Joint Venture, Nextpower Arabia

Energy Leaders Abunayyan Holding and Nextpower Complete Formation of Joint Venture, Nextpower Arabia

New Saudi manufacturing facility to produce advanced solar tracking systems for the Middle East and North Africa region

RIYADH, Saudi Arabia–(BUSINESS WIRE)–Nextpower (Nasdaq: NXT, formerly Nextracker) and Abunayyan Holding today announced the completion of the incorporation of the previously announced joint venture, Nextpower Arabia, headquartered in Riyadh, Kingdom of Saudi Arabia. The new joint venture will accelerate the deployment of utility-scale solar power plants across the Middle East and North Africa (MENA) region, supporting national and regional renewable energy transformation objectives and Net Zero targets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260111848469/en/

As part of the new joint venture, the partners also announced a new advanced manufacturing facility in Jeddah, Saudi Arabia. Nextpower Arabia will provide advanced tracker systems, yield management, and control solutions for installation on large-scale solar projects across the MENA region.

The facility is expected to enable total manufacturing and localized supply chain capacity of up to 12 GW per year, supporting the creation of up to 2,000 jobs and development of local engineering and technical talent within the Kingdom. Currently under construction on a 42,000-square-meter site, the production facility is anticipated to open in Q2 of calendar year 2026 and will manufacture Nextpower’s comprehensive portfolio of solar tracking systems, adding up to 600 employees (watch the video).

Khalid Abunayyan, Chairman of Abunayyan Holding, said, “Making energy and water supply readily accessible, sustainable, and affordable is essential to the continued economic and social development of Saudi Arabia and our partners across the region. It is also central to the core values and DNA of Abunayyan Holding. Partnering with Nextpower, a true pioneer in the international solar energy community, strengthens our role in advancing Saudi’s clean energy vision by localizing advanced manufacturing and technologies, building local capacity development, and creating lasting value for generations to come.”

Dan Shugar, founder and CEO of Nextpower, said, “Saudi Arabia is a strategic market for Nextpower as we expand our ability to serve customers across the Middle East. The Kingdom is making significant progress in advancing the energy transition, and we’re proud and honored to support these monumental initiatives with proven solar technology and trusted local partnerships. Abunayyan Group’s regional expertise and alignment with our business focus make them the right partner to help deliver greater value, faster, for customers in the region.”

Turki Al-Amri, Abunayyan Holding CEO and Nextpower Arabia Chairman and CEO, said, “Our manufacturing facility represents the first step in our strategic vision to strengthen and localize the solar supply chain for our partners across the MENA region and enhance collaboration to deliver highly efficient and cost-effective clean energy. By sourcing core materials such as Saudi-produced steel through our strategic partners and manufacturing locally, we are supporting economic diversification and industrial growth that is at the foundation of Saudi Vision 2030.”

Nextpower Arabia combines the deep regional expertise of Riyadh-based Abunayyan Holding with the global solar technology leadership of Nextpower. Abunayyan Holding brings more than 75 years of experience developing and privatizing the operation of critical water and energy infrastructure across Saudi and the MENA region. The company was a key driver of the consortium behind the founding and growth of several development arms and forming joint ventures that bring leading technology to the region.

U.S.-headquartered Nextpower is a global leader in advanced solar tracking systems and software, with over 150 GW of trackers under fulfilment or operational across more than 45 countries worldwide. This total includes more than 6 GW of solar projects across the Middle East and Africa, such as Phase V of the Mohammed Bin Rashid Al Maktoum Solar Park in the UAE and 3 GW of Saudi landmark projects, including:

Nextpower Arabia is well positioned to support the National Renewable Energy Program in the Kingdom of Saudi Arabia, which targets increasing the share of renewables in the country’s energy mix by 2030. Localizing manufacturing in the Kingdom will also support Saudi Arabia’s industrialization and export development plans while helping reduce the cost of clean energy for major projects across the region.

According to the Middle East Solar Industry Association’s (MESIA) recent 2025 Solar Outlook Report, cost competitiveness and improving production efficiencies are accelerating solar adoption and government-backed clean energy strategies, with regional solar capacity projected to exceed 180 GW by 2030.

In support of this growth opportunity, Abunayyan Holding and Nextpower anticipate funding the joint venture with approximately $88 million (approximately 330 million Saudi Riyals) in equity and public and private debt financings over the next two years alone. This capital will facilitate the buildout of the state-of-the-art manufacturing facility and development of highly skilled technical and engineering capabilities with a track record in operational excellence.

About Nextpower

Nextpower™ (Nasdaq: NXT, formerly Nextracker) designs, engineers, and delivers an advanced energy technology platform for solar power plants, innovating across structural, electrical, and digital domains. Our integrated solutions are designed to streamline project execution, increase energy yield and long-term reliability, and enhance customer ROI. Building on over a decade of technology and market leadership, the company delivers intelligent power generation systems and services to meet rapidly expanding global electricity demand. Nextpower partners with the world’s leading energy companies to power what’s next. Learn more at www.nextpower.com.

About Abunayyan Holding

Abunayyan Holding is one of Saudi Arabia’s most established and leading companies in the fields of water, energy, and infrastructure. With a legacy spanning more than 75 years of leadership and innovation, the company provides integrated solutions that contribute to sustaining life and supporting the Kingdom’s national development goals.

The Group comprises a portfolio of strategic subsidiaries covering the full value chain across water, renewable energy, treatment, industrial equipment, and smart infrastructure, serving both local and regional markets in Saudi Arabia and the broader Middle East and North Africa region.

Through its local and international partnerships, Abunayyan Holding plays a key role in localizing technologies and empowering national talent in alignment with the objectives of Saudi Vision 2030 to build a prosperous, sustainable, and innovation-driven economy.

For more information, please visit Abunayyan Holding.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including: statements regarding the deployment of utility-scale solar power plants in MENA and the ability to reach renewable energy objectives, including Net Zero targets; statements regarding the speed, cost efficiency and supply-chain optimization anticipated from the joint venture; statements regarding the development of manufacturing facilities and the benefits associated with such development, including capacity increases and job creation; and statements regarding the anticipated benefits of the joint venture, and future opportunities for the joint venture, including the benefits customers may realize as a result of the joint venture. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors including: the satisfaction of other closing conditions and the ability of Nextpower to successfully integrate operations and employees in the joint venture; the market demand for products, solutions and services offered by the joint venture and the joint venture’s ability to deliver them to customers; the risks of operating in the Kingdom and the MENA region; unexpected costs, charges or expenses resulting from the joint venture; the joint venture’s ability to successfully grow its business; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the joint venture; the retention of key employees, customers, or suppliers; projections regarding the global demand for electricity and solar power; macro-economic trends; and legislative, regulatory and economic developments, including changing business conditions in our industry or markets overall and the economy in general. These statements involve risks and uncertainties that could cause the actual results to differ materially from those anticipated by these forward-looking statements, including risks and uncertainties that are also described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Nextpower’s most recent Quarterly Report on Form 10-Q, Annual Report on Form 10-K and other documents that Nextpower has filed or will file with the Securities and Exchange Commission. There may be additional risks that Nextpower and/or the joint venture is not aware of or that Nextpower and/or the joint venture currently believes are immaterial that could also cause actual results to differ from these forward-

looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. Nextpower and the joint venture assume no obligation to update these forward-looking statements.

Sales Contact

Naif Makki (Nextpower Arabia)

[email protected]

IR Contact

Sarah Lee

[email protected]

Media Contacts

Jake Drake (MENA)

[email protected]

Sowmya Sriram (MENA)/

Brandy Lee (Global)

[email protected]

KEYWORDS: North America United States Saudi Arabia Middle East Africa California

INDUSTRY KEYWORDS: Alternative Energy Manufacturing Other Manufacturing Energy Utilities

MEDIA:

Photo
Photo
Logo
Logo